Open Access Repository

Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities

Nielsen, S, Sanfilippo, P, Belackova, V, Day, C, Silins, E, Lintzeris, N, Bruno, R ORCID: 0000-0001-6673-833X, Grebely, J, Lancaster, K, Ali, R, Bell, J, Dietze, P, Degenhardt, L, Farrell, M and Larance, B 2020 , 'Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities' , Addiction , doi: 10.1111/add.15297.

Full text not available from this repository.


Background and aims Not all people experiencing opioid dependence benefit from oral opioid agonist treatment. Theaim of this study was to examine perceptions of (supervised) injectable opioid agonist treatment (iOAT) (described as ‘anopioid similar to heroin self‐injected at a clinic several times a day’) among people who regularly use opioids and determinehow common iOAT eligibility criteria accord with interest in iOAT. Design Cross‐sectional survey Setting Sydney,Melbourne and Hobart, Australia. Participants A total of 344 people (63% male) who use opioids regularly and had everinjected opioids, interviewed December 2017–March 2018. The mean age of participants was 41.5 years [standarddeviation (SD) = 8.5]. Measurements Primary outcome measures were interest in iOAT, factors associated with interestand the proportion of participants who would be eligible using common criteria from trials and guidelines. We examinedwillingness to travel for iOAT, medication preferences and perspectives on whom should receive iOAT. Findings Overall,53% of participants (n = 182) believed that iOAT would be a good treatment option for them. Participants who believedthat iOAT was a good treatment option for them were more likely to be male [adjusted odds ratio (aOR) = 1.76, 95%confidence interval (CI) = 1.10–2.82], have used heroin in the past month (aOR = 6.03, 95% CI = 2.86–12.71), currentlyregularly inject opioids (aOR = 1.84, 95% CI = 1.16–2.91) and have met ICD‐10 criteria for opioid dependence(aOR = 3.46, 95% CI = 1.65–7.24). Those interested in iOAT had commenced more treatment episodes (aOR =1.06,95% CI = 1.00–1.12). Among those interested in iOAT (n = 182), 26% (n = 48) met common eligibility criteria for iOAT. Conclusions Interest in injectable opioid agonist treatment does not appear to be universal among people who regularlyuse opioids. Among study participants who expressed interest in injectable opioid agonist treatment, most did not meetcommon eligibility criteria.

Item Type: Article
Authors/Creators:Nielsen, S and Sanfilippo, P and Belackova, V and Day, C and Silins, E and Lintzeris, N and Bruno, R and Grebely, J and Lancaster, K and Ali, R and Bell, J and Dietze, P and Degenhardt, L and Farrell, M and Larance, B
Keywords: long acting buprenorphine, opioid dependence, consumer perceptions, heroin, injectable opioid agonist treatment, medication assisted treatment, opioid related disorders
Journal or Publication Title: Addiction
Publisher: Blackwell Publishing Ltd
ISSN: 0965-2140
DOI / ID Number: 10.1111/add.15297
Copyright Information:

Copyright 2020 Society for the Study of Addiction

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page